KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Debt (2020 - 2025)

Regeneron Pharmaceuticals has reported Non-Current Debt over the past 6 years, most recently at $2.0 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $2.0 billion for Q4 2025, changed 0.08% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (changed 0.08% YoY), and the annual figure for FY2025 was $2.0 billion, changed 0.08%.
  • Non-Current Debt for Q4 2025 was $2.0 billion at Regeneron Pharmaceuticals, roughly flat from $2.0 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for REGN hit a ceiling of $2.0 billion in Q3 2025 and a floor of $2.0 billion in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $2.0 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Non-Current Debt: increased 0.07% in 2021 and later increased 0.1% in 2025.
  • Regeneron Pharmaceuticals' Non-Current Debt stood at $2.0 billion in 2021, then rose by 0.07% to $2.0 billion in 2022, then grew by 0.08% to $2.0 billion in 2023, then increased by 0.08% to $2.0 billion in 2024, then rose by 0.08% to $2.0 billion in 2025.
  • The last three reported values for Non-Current Debt were $2.0 billion (Q4 2025), $2.0 billion (Q3 2025), and $2.0 billion (Q2 2025) per Business Quant data.